Short-term clinical outcomes among patients undergoing transcatheter aortic valve implantation in Switzerland: the Swiss TAVI registry
Peter Wenaweser, Stefan Stortecky, Dik Heg, David Tueller, Fabian Nietlispach, Volkmar Falk, Giovanni Pedrazzini, Raban Jeger, Oliver Reuthebuch, Thierry Carrel, Lorenz Räber, Franz W Amann, Enrico Ferrari, Stefan Toggweiler, Stephane Noble, Marco Roffi, Jürg Gruenenfelder, Peter Jüni, Stephan Windecker, Christoph Huber, Peter Wenaweser, Stefan Stortecky, Dik Heg, David Tueller, Fabian Nietlispach, Volkmar Falk, Giovanni Pedrazzini, Raban Jeger, Oliver Reuthebuch, Thierry Carrel, Lorenz Räber, Franz W Amann, Enrico Ferrari, Stefan Toggweiler, Stephane Noble, Marco Roffi, Jürg Gruenenfelder, Peter Jüni, Stephan Windecker, Christoph Huber
Abstract
Aims: To evaluate short-term clinical outcomes following transcatheter aortic valve implantation (TAVI) using CE-mark approved devices in Switzerland.
Methods and results: The Swiss TAVI registry is a national, prospective, multicentre, monitored cohort study evaluating clinical outcomes in consecutive patients undergoing TAVI at cardiovascular centres in Switzerland. From February 2011 to March 2013, a total of 697 patients underwent TAVI for native aortic valve stenosis (98.1%), degenerative aortic bioprosthesis (1.6%) or severe aortic regurgitation (0.3%). Patients were elderly (82.4±6 years), 52% were females, and the majority highly symptomatic (73.1% NYHA III/IV). Patients with severe aortic stenosis (mean gradient 44.8±17 mmHg, aortic valve area 0.7±0.3 cm²) were either deemed inoperable or at high risk for conventional surgery (STS 8.2%±7). The transfemoral access was the most frequently used (79.1%), followed by transapical (18.1%), direct aortic (1.7%) and subclavian access (1.1%). At 30 days, rates of all-cause mortality, cerebrovascular events and myocardial infarction were 4.8%, 3.3% and 0.4%, respectively. The most frequently observed adverse events were access-related complications (11.8%), permanent pacemaker implantation (20.5%) and bleeding complications (16.6%). The Swiss TAVI registry is registered at ClinicalTrials.gov (NCT01368250).
Conclusions: The Swiss TAVI registry is a national cohort study evaluating consecutive TAVI procedures in Switzerland. This first outcome report provides favourable short-term clinical outcomes in unselected TAVI patients.
Source: PubMed